Lung Cancer Archives

Highlights from ASCO 2022

VJOncology are excited to present our top picks from the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting!

FDA approves mobocertinib for NSCLC with EGFR exon 20 insertion mutations

The U.S. Food and Drug Administration (FDA) has granted accelerated approval of mobocertinib for patients with metastatic non-small cell lung…

Top 5 in lung from ASCO 2021

Highlights from ASCO 2021 in lung cancer! Learn more about the major clinical trials reported at this year’s meeting.

Top picks from ASCO 2021

VJOncology presents highlights from this year’s virtual American Society of Clinical Oncology (ASCO) annual meeting!

WCLC 2021 Highlights

VJOncology are pleased to bring you our top picks from the recent virtual WCLC meeting

First-line therapy with TKIs in NSCLC

Advances in treatment options for anaplastic lymphoma kinase (ALK+) non-small cell lung cancer (NSCLC) have improved patient outcomes considerably in…

ADAURA: osimertinib demonstrates significant clinical benefit in adjuvant NSCLC therapy

The first interim results of the Phase III ADAURA study evaluating adjuvant osimertinib in stage IB-IIIA EGFR-mutated non-small cell lung…

Multi-cancer detection and localization for more than 50 cancer types

The early detection of cancer improves outcomes for patients – in terms of both reducing treatment burden and improving the…

Use of pembrolizumab in patients with PS2 NSCLC

Clinical trials assessing the efficacy of pembrolizumab have previously enrolled patients with performance status (PS) 0–1. However, almost a fifth…

Further positive data published for lung cancer screening

The early detection of lung cancer is an exciting field with the potential to greatly improve patient survival. The topic…

Lung Cancer